According to findings from a preliminary study, researchers now believe that multiple sclerosis (MS) may not flare following pregnancy as had long been assumed. The study results will be presented at the American Academy of Neurology’s 71st Annual Meeting in Philadelphia, Pennsylvania, May 4-10, 2019.
According to findings from a preliminary study, researchers now believe that multiple sclerosis (MS) may not flare following pregnancy as had long been assumed. The study results will be presented at the American Academy of Neurology’s 71st Annual Meeting in Philadelphia, Pennsylvania, May 4-10, 2019.
Researchers reviewed records from Kaiser Permanente Southern and Northern California databases and identified 466 pregnancies among 375 women with MS from 2008 to 2016. The study investigators analyzed medical records and surveyed the women about treatment, breastfeeding, and relapses.
Among included participants, 38% had not been receiving MS treatment in the year prior to becoming pregnant. At the start of the pregnancy, 15% had clinically isolated syndrome, and 8% experienced a relapse during pregnancy. Conversely, in the year after giving birth, 26% of women experienced a relapse, 87% breastfed, 35% breastfed exclusively, and 41% started taking MS treatment again.
Prior to pregnancy, the annual relapse rate for the participants was 0.39. During pregnancy, the rate fell in the range of 0.07 to 0.014. Researchers noted that disease activity did not recur after birth as demonstrated by a relapse rate of 0.27 in the first 3 months after birth. The researchers remeasured the relapse rate at 4 and 6 months after birth, at which time the rate had returned to pre-pregnancy level, at 0.37.
“These results are exciting as MS is more common among women of childbearing age than in any other group. This shows us that women with MS today can have children, breastfeed, and resume their treatment without experiencing an increased risk of relapses during the postpartum period,” said study author Annette Langer-Gould, MD, PhD, in a statement.
Of note, women who breastfed exclusively were nearly 40% less likely to experience a relapse than women who did not breastfeed. Women who supplemented breast milk with formula within 2 months post delivery were just as likely to relapse as women who did not breastfeed at all. Of the women who breastfed exclusively, 46 out of 167 resumed MS treatment while breastfeeding.
The study authors recommended that future studies look at the subgroup of women who are treated with natalizumab or fingolimod prior to pregnancy, as those who take such medications tend to have a more severe form of MS. Future studies should analyze this subgroup so as to further investigate reported severe relapses related to stopping these specific treatments during pregnancy.
Reference
Good news for women with MS: disease may not worsen after pregnancy after all [press release]. Minneapolis: American Academy of Neurology; February 26, 2019. newswise.com/articles/view/708751/?sc=sphr&xy=10022175. Accessed March 18, 2019.
Patient-Reported Outcomes Reinforce Efficacy of Natalizumab for MS
November 21st 2023Researchers gathered data on patient-reported outcomes to support evidence for the continuation of natalizumab, a disease-modifying treatment, in the management of multiple sclerosis (MS) progression.
Read More
Timing of Neurofilament Light Changes May Predict Multiple Sclerosis Worsening
November 16th 2023The reported neurofilament light elevation preceding confirmed disability worsening events highlighted the value of NfL as an early biomarker of disability worsening and points to the existence of different windows of dynamic central nervous system pathology.
Read More
FDA Allows At-Home Dosing of Intranasal Foralumab for Multiple Sclerosis
October 23rd 2023The FDA’s decision to allow at-home dosing of intransal foralumab for patients with multiple sclerosis is likely to improve patient compliance to treatment and health outcomes, according to a recent release statement.
Read More